Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03813836
Other study ID # UCL/17/0396
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date July 5, 2019
Est. completion date January 31, 2026

Study information

Verified date June 2023
Source University College, London
Contact Emily Ambrose
Phone 020 7679 9483
Email ctc.poppy@ucl.ac.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A single-arm phase II trial to assess the efficacy and safety profile of pembrolizumab in patients with performance status of 2 with recurrent or metastatic squamous cell carcinoma of the head and neck. Patients will receive best supportive care + pembrolizumab 200mg every 3 weeks for a maximum duration of 24 months


Recruitment information / eligibility

Status Recruiting
Enrollment 65
Est. completion date January 31, 2026
Est. primary completion date July 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria 1. Histologically confirmed recurrent or metastatic squamous cell carcinoma of the head and neck that is considered incurable by local therapies. 2. Measurable disease evaluated by RECIST v1.1 3. WHO performance status of 2 4. Life expectancy of at least 12 weeks 5. Aged = 18 years of age 6. Adequate Bone marrow function: - Absolute neutrophils grade 0 or 1 (using CTCAE v5) - Platelets grade 0 or 1 - Haemoglobin grade 0 or 1 7. Adequate renal function: Creatinine grade 0 or 1 Calculated glomerular filtration rate (GFR) = 50 mL/min estimated using validated creatinine clearance calculation (e.g. Cockcroft-Gault or Wright formula). If calculated GFR is < 50 mL/min then an isotope GFR assessment (Cr51-EDTA or 99mTc-DTPA) should be performed. If an isotope GFR test is unavailable an estimation from 24 hour urine collection may be used 8. Adequate liver function: Serum bilirubin grade 0 or 1 AST and ALT grade 0 or 1 (up to grade 2 for patients with liver metastases) 9. Willing to use contraception for the duration of trial treatment and for 120 days after completion of treatment 10. Willing to have a new biopsy, if site of disease is accessible and considered safe to biopsy by investigator If newly obtained samples cannot be obtained (e.g. inaccessible disease or patient safety concern) sites may submit archival tissue only upon agreement from the sponsor 11. Able to give informed consent, indicating that the patient has been informed of and understands the experimental nature of the study, possible risks and benefits, trial procedures, and alternative options 12. Willing and able to comply with the protocol for the duration of the study, including the treatment plan, investigations required and follow up visits Exclusion Criteria: 1. Patients with undifferentiated nasopharyngeal or sino-nasal cancers 2. Disease suitable for treatment with curative intent 3. Prior therapy with an anti-PD-1, anti-PD-L1 or anti-PD-L2 agent 4. Any investigational agents within 4 weeks prior to registration 5. Anti-cancer monoclonal antibody therapy within 4 weeks prior to registration 6. Chemotherapy, targeted small molecule therapy, or radiotherapy within 2 weeks prior to registration 7. Patients with concurrent or previous malignancy that could compromise assessment of the primary or secondary endpoints of the trial 8. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment 9. Grade 3 or 4 peripheral neuropathy 10. Any serious and/or unstable pre-existing medical, psychiatric or other condition that, in the treating clinician's judgment, could interfere with patient safety or obtaining informed consent 11. Active central nervous system (CNS) metastases and/or carcinomatous meningitis; subjects with previously treated brain metastases may participate provided they: Are stable, without evidence of progression for at least four weeks prior to the first dose of trial treatment Have no evidence of new or enlarging brain metastases Have no evidence of leptomeningeal disease Are not using steroids for at least 7 days prior to trial treatment 12. Has a known history of or is positive for hepatitis B (hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (hepatitis C virus [HCV] RNA [qualitative] is detected) NB: Without known history, testing is required to determine eligibility. Hepatitis C antibody testing is allowed for screening purposes in sites where HCV RNA is not part of standard of care 13. Immunocompromised patients (e.g. known HIV positive status)* 14. Prior organ transplantation including allogenic stem-cell transplantation 15. Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids, or current pneumonitis/interstitial lung disease 16. Active infection requiring systemic therapy 17. Has received a live vaccine within 30 days prior to registration (seasonal flu vaccines that do not contain live virus are permitted) 18. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment (NB: the use of physiologic doses of corticosteroids may be approved after consultation with UCL CTC) 19. Active autoimmune disease that might deteriorate when receiving an immune-stimulatory agent. Patients with the following are eligible: Autoimmune-related hyperthyroidism or autoimmune-related hypothyroidism who are in remission or on a stable dose of thyroid-replacement hormone Vitiligo Psoriasis 20. Current use of immunosuppressive medication, except for the following: intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection) Systemic corticosteroids at physiologic doses = 10 mg/day of prednisolone or equivalent (after approval by UCL CTC) Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication) *Testing for HIV for the POPPY trial is not mandatory, however if this test has been done the result should be known prior to registration.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Pembrolizumab
Patients will receive best supportive care + pembrolizumab 200mg every 3 weeks for a maximum duration of 24 months

Locations

Country Name City State
United Kingdom Aberdeen Royal Infirmary (NHS Grampian) Aberdeen
United Kingdom Bristol Haematology and Oncology Centre (University Hospital Bristol NHS Foundation Trust) Bristol
United Kingdom Western General Hospital (NHS Lothian) Edinburgh
United Kingdom East Suffolk and North Essex NHS Foundation Trust Ipswich
United Kingdom Guy's and St Thomas' NHS Foundation Trust London
United Kingdom University College London Hospital London
United Kingdom The Christie NHS Foundation Trust Manchester
United Kingdom East and North Hertfordshire NHS Trust Northwood
United Kingdom Queens Hospital (Barking, Havering and Redbridge University Hospitals NHS Trust) Romford
United Kingdom Musgrove Park Hospital (Somerset NHS Foundation Trust) Taunton
United Kingdom Royal Cornwall Hospital Trust Truro
United Kingdom The Clatterbridge Cancer Centre NHS Foundation Trust Wirral

Sponsors (2)

Lead Sponsor Collaborator
University College, London Merck Sharp & Dohme LLC

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Disease control rate at 24 weeks assessed using iRECIST Disease control rate (proportion of patients with CR, PR or SD) assessed using iRECIST 24 weeks after registration
Secondary Disease control rate assessed using iRECIST Disease control rate (proportion of patients with CR, PR or SD) assessed using iRECIST 12 months after registration
Secondary Best Response Rate- measured using the change from baseline tumour size. Assessed using iRECIST. Best Response Rate, defined as proportion of patients who have a CR or PR as their best response, measured using the change from baseline tumour size, assessed using iRECIST 6 months after registration
Secondary Clinical Benefit Rate -defined as patient's best response rate lasting at least 18 weeks Clinical Benefit Rate, defined as proportion patients who have achieved CR, PR or SD as their best response lasting at least 18 weeks From start of treatment to 30 months post start of treatment
Secondary Duration of Response- defined as the time from first documented evidence of CR or PR until disease progression or death. Duration of Response, defined as the time from first documented evidence of CR or PR until disease progression or death From start of treatment to 30 months post start of treatment
Secondary Time to Progression -defined as time from registration to the first documented disease progression Time to Progression, defined as time from registration to the first documented disease progression From registration to 30 months post start of treatment
Secondary Progression Free Survival defined as the time from registration to the first documented disease progression or death due to any cause, whichever occurs first. Progression Free Survival, defined as the time from registration to the first documented disease progression or death due to any cause, whichever occurs first. From registration to 30 months post start of treatment
Secondary Overall Survival- defined as the time from registration to death due to any cause. Overall Survival, defined as the time from registration to death due to any cause. From registration to 30 months post start of treatment
Secondary Frequency and severity of adverse events- throughout the patient's treatment and until 6 months after completion of trial treatment. Frequency and severity of adverse events From date of registration until 6 months after completion of trial treatment
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03468218 - Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer Phase 2
Recruiting NCT05945875 - Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer Phase 1
Completed NCT03229278 - Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma Phase 1
Recruiting NCT05980000 - Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma Phase 2
Active, not recruiting NCT01468896 - Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery Phase 1/Phase 2
Recruiting NCT04862650 - Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Phase 2
Terminated NCT01602315 - A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Phase 1/Phase 2
Recruiting NCT05726370 - Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC Phase 2
Terminated NCT03823131 - Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat Phase 2
Terminated NCT03522584 - Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Phase 1/Phase 2
Completed NCT03032250 - Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck Cancer N/A
Withdrawn NCT04834349 - Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer Phase 2
Completed NCT04220775 - Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer Phase 1/Phase 2
Recruiting NCT06265285 - Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program Phase 2
Recruiting NCT05063552 - Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers Phase 2/Phase 3
Recruiting NCT04588038 - NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery Phase 1
Withdrawn NCT05359692 - INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Phase 2
Active, not recruiting NCT04282109 - Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX) Phase 2
Active, not recruiting NCT03521570 - Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer Phase 2
Recruiting NCT05156970 - Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC Phase 2